Not applicableUnknownNCT05308875What this trial is testingEfficacy and Safety Evaluation of PD1-BCMA-CARTWho this might be right forMultiple Myeloma Bioray Laboratories 9
Early research (Phase 1)Temporarily pausedNCT07340853What this trial is testingCRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma Thomas Martin, MD 30
Not applicableEnded earlyNCT00813501What this trial is testingImmunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other DiseasesWho this might be right forChronic Myeloproliferative DisordersGraft Versus Host DiseaseInfection+7 more City of Hope Medical Center 60
Testing effectiveness (Phase 2)Looking for participantsNCT07657312What this trial is testingInfliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory MyelomaWho this might be right forCytokine Release SyndromeRecurrent Multiple MyelomaRefractory Multiple Myeloma Naresh Bumma 35
Testing effectiveness (Phase 2)Ended earlyNCT04407442What this trial is testingDaratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With DaratumumabWho this might be right forRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma University of California, San Francisco 5
Early research (Phase 1)Study completedNCT03733717What this trial is testingEvaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Sanofi 25
Early research (Phase 1)Ended earlyNCT02978235What this trial is testingA Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or LymphomaWho this might be right forMultiple MyelomaNonHodgkin Lymphoma Taiho Oncology, Inc. 11
Testing effectiveness (Phase 2)Study completedNCT02046915What this trial is testingPhase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and CyclophosphamideWho this might be right forRelapsed or Refractory Multiple Myeloma University Hospital Tuebingen 60
Not applicableNo Longer AvailableNCT02204553What this trial is testingExpanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Novartis Pharmaceuticals
Early research (Phase 1)UnknownNCT04818372What this trial is testingDose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and LymphomaWho this might be right forMultiple MyelomaLymphoma Keymed Biosciences Co.Ltd 87
Testing effectiveness (Phase 2)Active Not RecruitingNCT03589222What this trial is testingSELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple MyelomaWho this might be right forRefractory Multiple Myeloma PETHEMA Foundation 62
Testing effectiveness (Phase 2)Study completedNCT00474929What this trial is testingSorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaWho this might be right forLymphomaMultiple Myeloma and Plasma Cell Neoplasm Mayo Clinic 103
Early research (Phase 1)Study completedNCT06082596What this trial is testingStudy of BEBT-908 in Subjects With Advanced Hematological TumorsWho this might be right forRelapsed or Refractory Non-Hodgkin's LymphomaRelapsed or Refractory Multiple Myeloma BeBetter Med Inc 32
Testing effectiveness (Phase 2)Ended earlyNCT02952573What this trial is testingTesting JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of ImprovementWho this might be right forMultiple MyelomaRelapsed/Refractory University Health Network, Toronto 20
Testing effectiveness (Phase 2)Study completedNCT00966693What this trial is testingLenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple MyelomaWho this might be right forRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma M.D. Anderson Cancer Center 77
Testing effectiveness (Phase 2)Study completedNCT02159365What this trial is testingStudy of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma PatientsWho this might be right forMultiple Myeloma Bristol-Myers Squibb 84
Early research (Phase 1)Study completedNCT05567887What this trial is testingLearn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic MalignanciesWho this might be right forLymphomaMultiple Myeloma Pfizer 7
Early research (Phase 1)Ended earlyNCT00744354What this trial is testingVorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma and Plasma Cell Neoplasm UNC Lineberger Comprehensive Cancer Center 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07107204What this trial is testingA Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic MalignanciesWho this might be right forRelapsed or Refractory Hematologic MalignanciesLeukemiaLymphoma+1 more Biotroy Therapeutics 116
Large-scale testing (Phase 3)Looking for participantsNCT07138209What this trial is testingA Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple MyelomaWho this might be right forRelapsed or Refractory Multiple Myeloma Qilu Pharmaceutical Co., Ltd. 228